Company Focus
Novo Nordisk
Latest Novo Nordisk News
Pharmaceutical
The US Food and Drug Administration’s (FDA) recent moves around GLP-1-based combination therapies are telling, not just about the agency’s evolving stance on obesity treatment, but about how it is reshaping its regulatory playbook for metabolic disease. 11 August 2025
Related News
Insights
Company Spotlight
A privately-held biotech company developing multiple-dose gene therapies to treat patients with genetic and idiopathic diseases, focusing first on hemophilia B.
Latest News & Features of interest to Novo Nordisk
Pharmaceutical
The US Food and Drug Administration (FDA) has approved a label update for Swiss pharma giant Novartis’ Leqvio (inclisiran), extending its use as monotherapy along with diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia. 4 August 2025
Biotechnology
Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla (donanemab-azbt) continued to demonstrate slowing of decline, with most participants having completed treatment, US pharma major Eli Lilly announced today. 4 August 2025
Pharmaceutical
Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective August 7, 2025. Mr Doustdar succeeds Lars Fruergaard Jørgensen, who will step down as president and chief executive officer on the same date. The company also announced other executive-level changes, effective August 7. 4 August 2025
Biotechnology
National Health Service (NHS) England has agreed to commission the use of Hemlibra (emicizumab) as a prophylactic treatment for patients of all ages with moderate hemophilia A with a severe bleeding phenotype who do not have factor VIII inhibitors. 2 August 2025
Pharmaceutical
US RNA interference (RNAi) specialist Arrowhead Pharmaceuticals today announced that its majority-owned subsidiary Visirna Therapeutics has signed an asset purchase agreement with France’s Sanofi to develop and commercialize four of Arrowhead’s investigational cardiometabolic candidates in Greater China. 2 August 2025
Biotechnology
US biotech major Biogen reported a 7% rise in its second quarter revenue Friday, with sales of $2.45 billion. 1 August 2025
Biotechnology
CSL Behring, a part of Australia’s’ CSL Limited, today announced that the board of directors of the Italian Medicines Agency (AIFA) has approved reimbursement of Hemgenix (etranacogene dezaparvovec). 1 August 2025
Pharmaceutical
US pharma major Eli Lilly has announced top-line results from SURPASS-CVOT, a first-of-its-kind head-to-head Phase III cardiovascular outcomes trial comparing two incretin therapies in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. 1 August 2025
Generics
Second quarter 2025 revenues at Teva Pharmaceutical Industries came in at $4.18 billion, flat in US dollars, or a decrease of 1% in local currency terms, compared to the same period of 2024. 31 July 2025
Pharmaceutical
Shares of Spanish plasma-derived medicines specialist Grifols rose 9% yesterday after it announced results for the first half of 2025, driven by a second quarter marked by continued improvements across key operational and financial metrics. These results reflect the ongoing execution of Grifols’ Value Creation Plan. 31 July 2025
Latest In Brief for Novo Nordisk
Pharmaceutical
Ireland-based biopharma Jazz Pharmaceuticals has been called out for a couple of indiscretions by The Prescription Medicines Code of Practice Authority (PMCPA), which was established by the Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry. 11 July 2025
Latest Related Ones To Watch News
Last week, a US Food and Drug Administration (FDA) advisory committee (AdCom) voted against approval of Danish drugmaker Lundbeck and Japan-based Otsuka’s Rexulti for post-traumatic stress disorder. France’s Sanofi announced it is expanding its respiratory vaccines pipeline with an up to $1.6 billion acquisition of UK biotech Vicebio. French biotech Abivax released new Phase III data on its investigational ulcerative colitis candidate obefazimod that saw its shares nearly quadruple. Also of note was the latest setback for Sarepta’s Duchenne muscular dystrophy drug Elevidys, when the European Medicines human health committee, the CHMP, declined partner Roche’s accelerated approval of the drug. 27 July 2025
17 June 2025
16 June 2025
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze